GlycArt Biotechnology AG

It Is A Risk Thing In times I’ve termed wilderness periods – the stagnant years for biotech stocks after a bubble bursts – investors shy away from exposure to the binary risk and funding requirements

BeiGene, Ltd. , Ascentage Pharma Group Corporation and I-Mab Biopharma Co., Ltd will be among the major Chinese biopharma companies reporting new clinical trial results for oncology drugs at the u

The anticancer antibodies Gazyva and Imfinzi have been launched in Japan following the granting of reimbursement prices under Japan’s national health insurance scheme on August 29, both at levels

Takeda Pharmaceutical Co. Ltd. ’s blockbuster gastrointestinal drug Entyvio (vedolizumab) has been approved in Japan, as a treatment and maintenance therapy for moderately to severely active ulcerat